CD274 and neoplasm: In addition to its effects on DCs, Bevacizumab has been shown to restore the TME to an immune supportive state by reducing the proportion of T-regs in the blood of patients with metastatic colorectal cancer [14] or ovarian cancer [22] and decreasing the number of PD-L1 positive tumour cells in glioblastoma patients [21].